MEA TAVR Market

MEA TAVR Market Size (2023 to 2028)

The size of the MEA transcatheter aortic valve replacement market is expected to be worth USD 0.90 billion by 2028 from USD 0.38 billion in 2023, growing at a CAGR of 18.995% from 2023 to 2028.

The key drivers of the MEA transcatheter heart valve replacement market are the growing demand for more minor invasive procedures for high-risk patients, the increasing prevalence of mitral regurgitation and severe aortic stenosis disorders, etc., in developing countries. The older population (over 75 years old) falls into the high-risk category because the open-heart procedure is too risky for them. Cardiovascular disorders such as aortic valve defect, stenosis or mitral regurgitation, rheumatic heart disease, or infective endocarditis affect the normal heart valves, mainly degenerative. TAVR involves the implantation of transcatheter aortic valves to regenerate/ restore the blood flow capacity of the aortic valve. Cardiovascular disease is also becoming a significant health problem in Gulf Council countries, including Saudi Arabia and the United Arab Emirates. Cardiovascular disease is estimated to account for over 47% of all deaths.

Factors such as shorter recovery time, fewer hospital stays, favorable outcomes with TAVR, and advancements in technology are also driving the adoption of this procedure over open-heart surgery, which is considered the gold standard. The prevalence of significant coronary artery disease as defined by angiography in patients with aortic valve disease has ranged from 22% to 64% in previous years. Approximately 35% of all CVD deaths, ischemic heart disease, and aortic stenosis are the most causative factors. Additionally, the growing patient population seeking effective and efficient treatment with high-quality healthcare facilities is another key factor driving the adoption of this new technique in the MEA region.

However, factors such as high costs of catheter-based heart valves, device-related complications associated post-surgery, poor reimbursement policies due to less clinical trials data, product recall by manufacturers, and technique sensitivity issues are assumed to be hampering the growth the market to some extent. Additionally, the market is also challenged by the lack of advanced healthcare infrastructure and the shortage of trained healthcare professionals.

This research report on the Middle East and Africa TAVR Market has been segmented and sub-segmented into the following categories:

By Surgery Method:

• Transfemoral Implantation
• Transapical Implantation
• Transaortic Implantation
• Transvaal Implantation                  

By Valve Material:

• Nitinol
• Stainless Steel
• Cobalt-Chromium              

By Valve Size:

• 14mm to 18 mm
• 18mm to 22 mm
• 22mm to 29mm                    

By Valve Leaflets Material:

• Bovine Heart Tissue
• Cow Heart Tissue
• Other Valve Leaflets Material                       

By End Users:

• Hospitals
• Ambulatory Surgical Centres
• Cardiac Catheterization Laboratories     

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Over the forecast period, the Middle Eastern countries are anticipated to dominate the MEA TAVR market. Middle Eastern countries such as Saudi Arabia, United Arab Emirates, Israel, Qatar, and Bahrain had a steady growth rate over the past several years and are anticipated to continue with the same trend for the years to come. Factors include the increasing geriatric population, improving healthcare infrastructure, and the increased demand for uncovered treatment procedures. In 2018, health spending as a percentage of Saudi Arabia's GDP was 6.5%. Saudi Arabia's GDP began to rise to 6.5 percent in 2018, from a low of 3% in 2008. Cardiovascular diseases are often referred to as the "silent killer" in the MEA region because mostly, the first warning sign of an underlying illness is unattended and ignored. Lack of facilities and an increased need for processing devices have led key players to invest in the Middle Eastern market.

Rapid urbanization has brought about a change in lifestyle, diet, risky behaviors, and cultural attitudes for the South African population. High blood pressure is the main complaint in the Sub-Saharan region, a significant risk factor for many CVDs. The prevalence is estimated at around 22 million in the African Region. The occurrence of cardiac disorders is expected to increase in the coming years, which positions South Africa as one of the emerging countries favoring the growth of the MEA TAVR market. This is estimated to open many growth opportunities to meet the unmet market demand during the forecast period.

KEY MARKET PLAYERS:

Some of the key participants in the MEA TAVR Market profiled in this report are Edwards Lifesciences Corporation, Medtronic, Inc., Boston Scientific Corporation, Abbott Laboratories, St. Jude Medical Inc., JenaValve Technology, Inc., Symetis SA, Direct Flow Medical, Inc., Sorin Group, Meril Life Sciences India Pvt Ltd and Braile Biomedica.